Skip to main content
    R

    Regeneron Pharmaceuticals Inc (REGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $952.40
    -3.07 (-0.32%)

    Market Cap: $98.84B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Regeneron Pharmaceuticals Inc (REGN) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Regeneron Pharmaceuticals (REGN) trades at 18.4x trailing earnings and 5.7x sales. Its P/E of 18.4x is above its 5-year median of 16.4x. Its forward P/E is 14.0x. The median P/E across 5 similar companies is 33.5x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 31.4% higher over the next year. Its free cash flow yield is 4.0%.

    MultipleValue
    P/E (trailing)18.4x
    Forward P/E14.0x
    Price to sales5.7x
    Price to book2.9x
    EV/EBITDA15.2x
    Price to FCF25.3x
    EV/FCF24.9x
    PEG1.2
    FCF yield4.0%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 8.9% above 16.9x, its P/S is 10.9% below 6.4x and its P/B is 23.7% below 3.8x.

    MultipleCurrent5-year median10-year median
    P/E18.4x16.4x16.9x
    P/S5.7x5.6x6.4x
    P/B2.9x3.3x3.8x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 8.4x in 2021 to 31.8x in 2016.

    Year endPriceP/EP/SP/B
    2025$771.8717.4x5.7x2.7x
    2024$712.3315.6x5.5x2.8x
    2023$878.2920.1x7.3x3.8x
    2022$721.4916.0x6.5x3.6x
    2021$631.528.4x4.2x3.8x
    2020$483.1115.3x6.2x4.9x
    2019$375.4815.2x6.3x3.9x
    2018$373.5016.4x7.9x4.9x
    2017$375.9623.1x7.0x7.1x
    2016$367.0931.8x8.1x9.6x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About REGN

    What is REGN's forward P/E ratio?

    Regeneron Pharmaceuticals has a forward P/E ratio of 14.0x.

    Is REGN stock overvalued?

    GNG's valuation label for REGN is Undervalued. Its P/E of 18.4x compares with a median of 33.5x across 5 similar companies.

    What is REGN's price to sales ratio?

    Regeneron Pharmaceuticals has a price to sales ratio of 5.7x.

    What is Regeneron Pharmaceuticals's average P/E ratio over 5 years?

    Regeneron Pharmaceuticals's median P/E over the last 5 years is 16.4x, from 60 month-end values through Oct 2026.

    What is REGN's PEG ratio?

    Regeneron Pharmaceuticals has a PEG ratio of 1.2.